Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

187.92 -2.81 (-1.47%)
Streaming Delayed Price Updated: 11:19 AM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
News headline image
What 14 Analyst Ratings Have To Say About Biogen ↗
 
Via Benzinga
News headline image
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
News headline image
European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen ↗
Eli Lilly's donanemab faces a setback as EMA's CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases. 
Via Benzinga
News headline image
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025 ↗
Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company. 
Via The Motley Fool
News headline image
How Is The Market Feeling About Biogen? ↗
 
Via Benzinga
News headline image
Biogen Analysts Lower Their Forecasts After Q4 Results ↗
 
Via Benzinga
News headline image
Forecasting The Future: 10 Analyst Projections For Biogen ↗
 
Via Benzinga
News headline image
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
From Biogen Inc.
Via GlobeNewswire
News headline image
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst... 
Via StockStory
Topics Artificial Intelligence
News headline image
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
News headline image
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
News headline image
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy ↗
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option. 
Via Benzinga
News headline image
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
From Biogen Inc.
Via GlobeNewswire
News headline image
Indexes Swimming In Red Ink On Recession Fears ↗
Stocks are looking to extend last week's losses, as recession fears grip Wall Street. 
Via Talk Markets
Topics Economy Stocks / Equities
News headline image
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding ↗
NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs and limited benefit. Stakeholders can submit feedback until March 27, 2025,... 
Via Benzinga
News headline image
Stocks Plummet As Trade Partners Retaliate Against Tariffs ↗
Stocks are free falling as President Donald Trump's tariffs against Mexico, Canada, and China take effect. 
Via Talk Markets
Topics Government Stocks / Equities World Trade
News headline image
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now trades at $140.49. This was partly driven by its softer quarterly results and... 
Via StockStory
News headline image
Synchronicity: Denying The Unexplainable ↗
Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph? 
Via Talk Markets
Topics Stocks / Equities
News headline image
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects ↗
Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing... 
Via Benzinga
News headline image
Biogen Stock Is Mutating Into a Value Play
Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X 
Via MarketBeat
News headline image
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal ↗
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments. 
Via Benzinga
News headline image
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Biogen Inc.
Via GlobeNewswire
News headline image
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts ↗
Biogen's Q4 EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers. 
Via Benzinga
News headline image
Top S&P500 movers in Wednesday's session ↗
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
News headline image
Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook ↗
Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop. 
Via Benzinga
News headline image
These S&P500 stocks have an unusual volume in today's session ↗
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below. 
Via Chartmill
News headline image
These S&P500 stocks are moving in today's session ↗
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
News headline image
Biogen (BIIB) Q4 2024 Earnings Call Transcript ↗
BIIB earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday? ↗
A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New... 
Via Benzinga
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.